http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1268599-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a09fa84c54c24536575f7f12c1f1db43 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C247-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D319-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0093 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C309-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C309-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D305-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D319-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 |
| filingDate | 1985-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1990-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36de97aa6cbc0974623fd2ef0a5dcf10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66cb3fcd54bbe9cd8b58737c1f7deceb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac3c84f72af24f79a316c6651b961b53 |
| publicationDate | 1990-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1268599-A |
| titleOfInvention | Cis-platinum complexes with a pentaerythritol derivative as the ligand, a process for their preparation and a pharmaceutical agent containing these compounds |
| abstract | Abstract of the disclosure: Compounds of the general formulae I and II Formula I Formula II in which R1 and R2 independently of one another represent H (CH2)a-(O-CH2)b)c-O where a = 0 to 4, b = 1 to 4 and c = 1 to 7, an alkoxy or arylalkoxy group with 1 to 20 carbon atoms, an alkane- or aralkanesulfonyloxy group with 1 to 7 carbon atoms or a tetrahydropyranyloxy radical, or R1 and R2 together represent an oxygen atom bonded in an ether-like manner or an acetal or ketal radical where R3 and R4 1ndependently of one another represent a hydrogen atom, an alkyl group with 1 to 20 carbon atoms of a phenyl group, A1 and A2 are identical Dnd represent a hydroxyl group, chloride, bromide, iodide, nitrate, acetate, trifluoro-acetate, trifluorosulfonate or perchlorate, or A1 represents sulfare or carbonate ion and A2 represents H2O, or A1 and A2 together represent the dianion of an organic acid, such as oxalic, malonic, hydroxymalonic, ethylmal-onic, succinic, maleic, aconitic, 3,6,9-trioxaundecanedioic, 1,1- or 1,2-cyclobutanedicarboxylic, phthalic, 3- or 4-carboxyphthalic or 3,4-dicarboxyphthalic acid, or A1 and A2 together represent a recurring anionic unit of a polymeric compound, such as dextran sulfate, chon-droitin sulfate or galactan sulfate, polyglutamic acid or polyitaconic dcid, and a process for their preparation and a medicanent containing these compounds are described. The compounds of the general Formulae I and II have anti-tumoral activity. |
| priorityDate | 1984-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 213.